Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations
Authors:
- Cynthia A. JackeviciusCJCynthia A. Jackevicius
- Elham RahmeERElham Rahme
- Vidal EssebagVEVidal Essebag
- Mark J. EisenbergMEMark J. Eisenberg
- Karin H. HumphriesKHKarin H. Humphries
- Jack V. TuJTJack V. Tu
- Hassan BehlouliHBHassan Behlouli
- Jennifer JooJJJennifer Joo
- Louise PiloteLPLouise Pilote
- 11 July 2011
- journal article
- research article
- Published by CMA Impact Inc. in Canadian Medical Association Journal
- Vol. 183 (12) , E817-E823
Abstract
Background: Amiodarone is associated with dysfunction of the thyroid. Concerns have arisen regarding the potential for adverse effects with generic formulations of amiodarone. We evaluated and compared the risk of thyroid dysfunction between patients using brand-name versus generic formulations of amiodarone and identified risk factors for thyroid dysfunction. Methods: We conducted a retrospective cohort study of patients with atrial fibrillation aged 66 years and older. We used administrative databases that linked information on demographics and clinical characteristics, claims for prescription drugs and discharges from hospital. We estimated thyroid dysfunction using person-year incidence. Results: Of the 60 220 patients in the cohort, 2804 (4.7%) used the brand-name formulation of amiodarone and 6278 (10.4%) used the generic formulation. Baseline characteristics between these two groups were comparable. The median maintenance dose of amiodarone was 200 mg/d for both groups. The total incidence rate for thyroid dysfunction was 14.1 per 100 person-years for both formulations. The mean time to clinical dysfunction of the thyroid was 4.32 years for the brand-name formulation and 4.09 years for the generic formulation. In a multivariate analysis, there was no significant difference in the incidence rates of thyroid dysfunction between the generic and brand formulations (hazard ratio 0.97, 95% confidence interval 0.87–1.08). Factors associated with an increased risk of thyroid dysfunction were being a woman, increasing age and having chronic obstructive pulmonary disease. Interpretation: In this population-based study, we saw no difference between brand-name and generic formulations of amiodarone in terms of incidence of thyroid dysfunction.Keywords
This publication has 31 references indexed in Scilit:
- Is there variability in drug release and physical characteristics of amiodarone chloride from different commercially available tablets? Possible therapeutic implicationsInternational Journal of Pharmacy Practice, 2010
- Rhythm control agents and adverse events in patients with atrial fibrillationInternational Journal Of Clinical Practice, 2010
- Effects of amiodarone therapy on thyroid functionNature Reviews Endocrinology, 2009
- How frequently should a patient taking amiodarone be screened for thyroid dysfunction?Brazilian Journal of Medical and Biological Research, 2009
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidismWiener klinische Wochenschrift, 2008
- Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticalsHealth Policy, 2007
- The Effects of Amiodarone on the ThyroidEndocrine Reviews, 2001
- Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias11∗Disclosure: This study was not written with support from or discussion with any pharmaceutical manufacturer.The American Journal of Cardiology, 2000
- Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidismThe American Journal of Medicine, 1991